Tesofensine
Also known as: NS2330
Serotonin-norepinephrine-dopamine reuptake inhibitor (triple reuptake inhibitor) that reduces appetite and increases energy expenditure.
- Typical dose
- 250 mcg – 1 mg
- Frequency
- once daily
- Route
- Oral
- Half-life
- 9.70833 days
- Routes
- Oral
- Status
- Phase III trials: not FDA approved
Benefits
- Significant weight loss
- Appetite suppression
- Increased energy expenditure
- Improved metabolic markers
Dosing
A common research range for Tesofensine is 250 mcg to 1 mg once daily. Oral tablet; start low and titrate. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Tesofensine has an approximate half-life of 9.70833 days. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
Room temperature.
Reported side effects
- Increased heart rate
- Dry mouth
- Insomnia
- Nausea
- Constipation
Contraindications
- Uncontrolled hypertension
- Cardiovascular disease
- MAO inhibitor use
Track Tesofensine with Vial
Vial logs every Tesofensine dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Tesofensine is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.